Frequently asked questions.

Visual field testing (also known as perimetry) is used to assess peripheral vision in each eye. It is the primary tool for detecting and monitoring glaucoma and other conditions that affect the visual pathway.

Visual field testing allows for early detection of glaucoma. If detected early, glaucoma can be halted, saving people from irreversible vision loss. Glaucoma is the most common cause of preventable blindness globally, yet most cases go undetected because the condition is asymptomatic in its early stages.

Any PC, laptop or tablet with a camera and an internet connection: it's your choice of device, no specialised hardware required.

Our software has been validated across 14 peer-reviewed clinical studies, demonstrating high accuracy in detecting visual field defects comparable to traditional in-clinic methods. Intraclass correlations for Mean Deviation reach 0.93 against the gold-standard Humphrey Field Analyzer, confirming clinical equivalence.

We have completed extensive comparative and population studies showing excellent correlation with the classic Humphrey analyser (MD ICC = 0.93, PD ICC = 0.86). Reports follow HFA conventions, including grey scale, total deviation, pattern deviation and global indices, so results sit alongside prior Humphrey Field Analyzer reports without any reformatting.

The software uses a Bayesian predictor to return the visual field threshold based on a patient's response to spots of different brightness. It achieves results equivalent to standard equipment in less time, with a similar level of accuracy. This approach is similar to Humphrey's SITA technique but has been optimised for fast, reliable outcomes, typically 2–3 minutes per eye.

24° visual field (glaucoma), 30° (neurological), 10° (macular / advanced glaucoma), binocular driver's licence, and monocular pilot's licence. Grid patterns are optimised for glaucoma, maculopathy/AMD, diabetes, and neurological diseases.

Yes. Our software is specifically designed for at-home use, with AI guidance plus video and written guides. In a published 6-month home monitoring study, at-home results were consistent with clinic results and showed acceptable repeatability. We recommend a patient's first test be completed in clinic for clear guidance on setup and positioning.

Yes. Our software supports threshold testing and screening assessments for early detection and monitoring of glaucoma. It includes progression analysis tools to track visual field changes over time. Its telehealth capability allows remote testing, reducing the need for frequent clinic visits, valuable for patients in remote locations or with limited mobility.

The test generates a map of your peripheral vision. The Sensitivity maps show how sensitive your vision is at each testing spot. Your scores are compared to age-matched normal values to generate Total Deviation displays. Focal defects are shown in the Pattern Deviation displays, the lower Pattern Deviation map is the most diagnostically important. The VFI (Visual Field Index) gives an overall percentage score out of 100, where 100% represents a completely normal visual field.

Yes, the VFI (Visual Field Index) shows a percentage out of 100 of your eye's overall visual field compared to normal. MD (Mean Deviation) and PSD (Pattern Standard Deviation) are more technical indices used by clinicians to analyse other aspects of the field.

Most patients with glaucoma are advised to have 6 tests within the first 2 years, then every 6 months. Higher-risk patients may need testing every 3–4 months. People at risk of glaucoma should be tested every 6–12 months. Our home-monitoring capability makes frequent testing practical and accessible.

The test includes reliability metrics: False Positive rate, False Negative rate, and Fixation Losses. If these are too high, the result will be marked as "Low Test Reliability" and your clinician will be alerted. Otherwise, you can be confident the result is high quality.

Our software continuously monitors head position and eye gaze via the device camera. If you move too close, too far, or look away from the fixation target, the test pauses automatically. On-screen and verbal instructions guide you back into the correct position before the test resumes.

A normal visual field is reassuring, but it does not rule out all eye conditions. In early glaucoma, the visual field may still appear normal. Visual field testing is complementary to a full clinical evaluation, we do not recommend testing without professional oversight.

Not necessarily. There are many causes of an abnormal visual field, of which glaucoma is just one. The test can sometimes produce spurious results with nothing wrong with your eyes. It is always best to have an abnormal result reviewed by an eye care professional.

Yes. The software uses a blind-spot monitor to gauge fixation accuracy, a procedure common to most perimeters. It locates the patient's blind spot at the start of the test, then periodically shows stimuli there to confirm accurate fixation. The blind spot appears as a gap in the visual field graphic on the printout. False positive rates, false negative rates, and fixation losses are all shown in the report header.

Conventional perimeters still use grid and spot-size approaches unchanged since Goldmann. Eyeonic improves on this in several ways: a spot size that increases with eccentricity to reduce threshold variability; an expanding test grid to define the edges of vision loss; and a Bayesian threshold predictor with neighbourhood logic for fast, reliable results. It also includes four disease-specific grid patterns (glaucoma, maculopathy/AMD, diabetes, neural diseases) and three forms of acuity testing.

Yes. Eyeonic has been used extensively by Dr Viney Gupta's team at the Department of Ophthalmology, AIIMS, New Delhi. Studies on glaucoma adults and children with congenital glaucoma have been conducted. Additionally, high performance has been demonstrated in Hindi- and Chinese-speaking populations, with 97% of participants agreeing on ease of use.

Our visual field test is sensitive to diabetes-related vision loss, detecting defects even before they are visible on retinal examination. It is useful for detecting and monitoring diabetic retinopathy and macular dysfunction, and can be incorporated into routine diabetes screening.

Yes. Its comprehensive reporting features allow ophthalmologists and optometrists to access, review, and share results easily. Reports can be sent directly to a nominated clinician or emailed to the patient. The platform is designed to complement existing workflows rather than replace them.

Eyeonic is a registered medical device in India (CDSCO Class A), USA (FDA), Europe (CE Mark), UK (UKCA), Australia (TGA), and several other countries, with more registrations in process.

Security was designed with Microsoft to the highest standards on Microsoft Azure. The AI uses head shape only to keep you correctly positioned, it does not capture facial features or biometric data. Results are visible only to you and your nominated clinician.

The header of the test result contains quality information including false positive rates, false negative rates, and fixation losses. These metrics follow the same conventions used by the Humphrey Field Analyzer for easy interpretation.

Our software is built on the clinical expertise of Eyeonic's founder, A/Prof Skalicky, a practising ophthalmologist. The application uses AI to continuously monitor and optimise head position throughout the test, and incorporates patented features for the test targets, all grounded in published research. This combination of clinical design, AI monitoring and peer-reviewed validation sets it apart from other software-based perimetry tools.

Yes. It is a web-based application that runs on any compatible device with a camera and internet connection. It can be used simultaneously across multiple computers in the same clinic or across different branches under a single account.

Yes. Test results can be sent directly to the patient via email. Note that the result link requires the recipient to log in before accessing the report, ensuring results remain private and secure.

From the test result screen, click Print Page. To ensure the report prints correctly, enable the "Background graphics" or "Print backgrounds" option in your browser's print settings. To save as a PDF, select Save as PDF in the printer screen and choose your file location.

This feature is currently in development. Once available, it will allow clinicians to view our results alongside historic Humphrey data for seamless progression monitoring.